Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13722428 | 0.81 | SMYD2 (0.30) | SMYD2 | |
| SCHEMBL707765 | 0.80 | TDP1 (0.35) | SMYD2 | |
| SCHEMBL14295864 | 0.76 | MGAM (0.30) | — | |
| SCHEMBL13722137 | 0.75 | SMYD2 (0.31) | SMYD2 | |
| SCHEMBL13722258 | 0.75 | LGALS9 (0.31) | SMYD2 | |
| SCHEMBL15906211 | 0.74 | — | — | |
| SCHEMBL15489103 | 0.73 | CNR1 (0.31) | ABCB1 | |
| SCHEMBL13721968 | 0.73 | TDP1 (0.35) | SMYD2 | |
| SCHEMBL12851720 | 0.73 | SMYD2 (0.33) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL13722088 | 0.73 | LMNA (0.34) | SMYD2ABCB1CYP3A4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140357856-A1 | CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY | ISIS PHARMACEUTICALS, INC. (US) | 2014-12-04 | — | — | US | disclosed |
| US-7696345-B2 | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation | ISIS PHARMACEUTICALS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20080039618-A1 | POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION | ALLERSON CHARLES | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039618-A1 | POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION | HNRNPC, SNRPE, IGF2BP1 | SMYD2 1359/4885ABCB1 3986/4885CYP3A4 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.